Naltrexone (Vivitrol) prior authorization at Highmark
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Highmark requires prior-authorization documentation for Naltrexone (Vivitrol): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Highmark reviews Naltrexone (Vivitrol) prior authorizations against its medical policy . Highmark-specific context: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Highmark's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Prior auth on biologics
- PA on advanced imaging
- OON balance bills
Naltrexone (Vivitrol)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy
- Frequency reduction
Oral and extended-release (Vivitrol) formulations. Used for OUD and AUD.
Manufacturer patient-assistance program: Alkermes Patient Access — relevant when a Highmark denial sticks and the patient needs bridge access while appealing.
How Highmark approaches Medications for Opioid Use Disorder (MOUD) PAs
For Naltrexone, check the current Highmark Medications for Opioid Use Disorder (MOUD) policy for MHPAEA-compliant prior-auth pathway and DEA X-waiver / prescriber-eligibility documentation under the 2023 Consolidated Appropriations Act removal of the X-waiver. Pharmacy-benefit review for Naltrexone at Highmark is routed through Express Scripts. The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Highmark; if denied, use the filing date and route printed on that denial notice. MHPAEA non-quantitative-treatment-limitation analysis applies — request Highmark's written NQTL comparative analysis under the 2023 final rule when the MOUD denial appears stricter than comparable medical-side prior auth. Highmark is domiciled in PA, so unresolved appeals escalate to the PA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.highmark.com/provider) with the same packet plus an applicable, current clinical source supporting Naltrexone (Vivitrol)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Highmark denial on DenialHelp.
Contact Highmark
- Provider portal: https://www.highmark.com/provider
Frequently asked questions
What documentation does Highmark need for Naltrexone (Vivitrol) prior auth?
Highmark's typical PA packet for Naltrexone (Vivitrol): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Highmark?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for Naltrexone (Vivitrol) at Highmark?
Preparation scenarios to check against the current notice and policy include: Prior auth on biologics; PA on advanced imaging; OON balance bills. These are not measured frequency claims. For Naltrexone (Vivitrol), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Can Highmark apply step therapy to MOUD like Naltrexone?
MHPAEA prohibits non-quantitative treatment limitations on MOUD that are stricter than the limits on comparable medical/surgical benefits. Request Highmark's written NQTL comparative analysis under the 2023 MHPAEA final rule. State Medicaid MCO plans are additionally required to cover all FDA-approved MOUD products without step therapy under the SUPPORT Act (2018) and related state plan amendments. Pharmacy-benefit handling is routed through Express Scripts. External-review escalation for Highmark fully-insured policies sits with the PA insurance department.
How do I prep for a peer-to-peer with Highmark on Naltrexone (Vivitrol)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Naltrexone (Vivitrol) PA packet
Open ApprovalHelp — generate a Naltrexone (Vivitrol) prior-auth packet tailored to Highmark's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com